ABSTRACT
In recent decades, increasing longevity (among other factors) has fostered a rise in Parkinson’s disease (PD) incidence. Although not exhaustively studied in this devastating disease, the impact of sex represents a critical variable in PD as epidemiological and clinical features differ between males and females. To study sex bias in PD, we conducted a systematic review, tissue-specific meta-analyses of transcriptomic data from the frontal cortex (FC), striatum tissue (ST), and substantia nigra (SN), and a global meta-analysis of all 3 brain regions. We selected 7 PD studies that included sex information, analyzing 267 samples. The tissue-specific meta-analyses linked PD to the enhanced expression of MED31 in the female FC and the dysregulation of 237 genes in the SN. The global meta-analysis detected 15 genes with sex-differential patterns in PD, which participate in mitochondrial function, oxidative stress, neuronal degeneration, and cell death. Furthermore, functional analyses identified pathways, protein-protein interaction networks, and transcription factors that differed by sex. While male PD patients exhibited changes in oxidative stress based on metal ions, inflammation, and angiogenesis, female PD patients exhibited dysfunctions in mitochondrial and lysosomal activity, antigen processing and presentation functions, and glutamic and purine metabolism. Overall, we believe that our findings will provide new insight into the perspective of sex in PD, thereby underscoring the importance of including sex information in future PD studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by GV/2020/186
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Gene Expression Omnibus (GEO) and ArrayExpress databases
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have updated some sections
Data Availability
DATA AVAILABILITY. The data used for the analyses described in this work is publicly available at GEO (https://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (https://www.ebi.ac.uk/arrayexpress/). The accession numbers of the GEO datasets downloaded are: GSE8397, GSE20295, GSE7621, GSE20146 and GSE28894. The accession numbers of the ArrayExpress datasets downloaded are: E-MTAB-1194 and E-MEXP-1416.
ABBREVIATIONS
- FC
- Frontal cortex
- GEO
- Gene Expression Omnibus
- LFC
- Log2 fold change
- NES
- Normalized enrichment score
- ORA
- Over-representation analysis
- PD
- Parkinson’s disease
- PPI
- Protein-protein interaction
- PRISMA
- Preferred reporting items for systematic reviews and meta-analyses
- SN
- Substantia nigra
- ST
- Striatum
